410074-60-1

Usage

Appearance

White to off-white solid

Solubility

Sparingly soluble in water

Uses

a. Intermediate in the synthesis of pharmaceuticals and agrochemicals
b. Production of various drugs, including antihypertensive and anti-inflammatory medications

Applications

a. Organic synthesis
b. Chemical research

Reactivity

Versatile

Stability

Stable

Industrial and scientific uses

Numerous, including pharmaceutical and agrochemical development

Upstream product

• 5180-28-9 N-butyl-carbonochloridimidic hypochlorous thioanhydride 
• 109-90-0 ethyl isocyanate 
• 592-82-5 butyl isothiocyanate 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF RGS PROTEINS

The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases)

Small molecule inhibitors of regulators of G protein signaling (rgs) proteins

Recently, regulators of G protein signaling (RGS) proteins have emerged as potential therapeutic targets since they provide an alternative method of modulating the activity of G protein-coupled receptors, the target of so many drugs. Inhibitors of RGS proteins must block a protein-protein interaction (RGS-Gα) but also be cell and, depending on the therapeutic target, blood-brain barrier permeable. A lead compound (1a) was identified as an inhibitor of RGS4 in a screening assay, and this has now been optimized for activity, selectivity, and solubility. The newly developed ligands (11b and 13) display substantial selectivity over the closely related RGS8 protein, lack the off-target calcium mobilization activity of the lead 1a, and have excellent aqueous solubility. They are currently being evaluated in vivo in rodent models of depression.

First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

Glycogen synthase kinase 3 β (GSK-3β) has a central role in Alzheimer′s disease (AD). Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutical approach to the AD pharmacotherapy and other neurodegenerative disorders